biomarker

(redirected from biomarkers)
Also found in: Dictionary, Encyclopedia.

marker

 [mahr´ker]
something that identifies or that is used to identify; see also determinant.
cell-surface marker an antigenic determinant found on the surface of a specific type of cell.
tumor marker a biochemical substance indicative of presence of a tumor; ideally, it should be specific, sensitive, and proportional to tumor load. Called also biomarker.

biomarker

(bī-ō-mark'ĕr),
A detectable cellular or molecular indicator of exposure, health effects, or susceptibility, which can be used to measure the absorbed, metabolized, or biologically effective dose of a substance, the response to the substance including susceptibility and resistance, idiosyncratic reactions, and other factors or conditions.

biomarker

/bio·mark·er/ (bi´o-mahr″ker)
1. a biological molecule used as a marker for a substance or process of interest.

biomarker

(bī′ō-mär′kər)
n.
1. Medicine
a. A physiological substance, such as human chorionic gonadotropin or alpha-fetoprotein, that when present in abnormal amounts in the serum may indicate the presence of disease, as that caused by a malignancy.
b. A specific physical trait used to measure or indicate the effects or progress of a disease or condition: Biomarkers of aging include thinning of the hair. Also called biosignature.

biomarker

(1) A characteristic which is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention.
(2) A molecular indicator of a specific biological property or function that can be measured in blood or other body fluids or tissues; a biochemical feature or facet that can be used to suggest the presence of a particular disease, measure its progress or the effects of treatment.
 
Examples
PSA for prostate cancer, Hb1a for glucose control in diabetics, troponin I for acute MI.

biomarker

Diagnostic medicine Any relatively specific biochemical parameter–eg, PSA, Hb1a or troponin I which, when found in ↑ amount in the blood, other body fluids, or tissues, suggest the presence of certain diseases or cancers. See Cardiac marker, Tumor marker.

bi·o·mark·er

(bīō-mahr-kĕr)
A detectable cellular or molecular indicator of exposure,health effects, or susceptibility, which can be used to measure the absorbed, metabolized, or biologically effective dose of a substance, the response to the substance including susceptibility and resistance, idiosyncratic reactions, and other factors or conditions.

Biomarker

A biochemical substance that can be detected in blood samples and indicates the presence of a cancerous tumor.
Mentioned in: Ovarian Cancer

bi·o·mark·er

(bīō-mahr-kĕr)
A detectable cellular or molecular indicator of exposure, health effects, or susceptibility, which can be used to measure the absorbed, metabolized, or biologically effective dose of a substance, the response to the substance including susceptibility and resistance, idiosyncratic reactions, and other factors or conditions.

biomarker,

n a short-lived radioactive molecule that can be used as a marker to follow a condition or a process.

biomarker

a biological unit used as an indirect indicator of the impact of pollutants on biota, e.g. an enzyme such as mixed function oxygenase levels, immune status of animals in the receiving environment.

Patient discussion about biomarker

Q. what is a safe tumor marker number range?

A. depends on the marker...most of the markers are materials that found normally in our body. and there are a number of markers and their levels differentiate. what marker do you mean?

Q. My wife(53) has elevated CEA and CA19.9 levels - near 150, without any concomitant reason/observation? Comment

A. Hi Bobby3,

The most important question is why were these tests done?
An elevated level may result from many causes, some of them are simple and some are more problematic. IMHO the best thing would be consulting her doctor to consider the need to check-up her alimentary system.
You can read more here (http://www.ascocancerfoundation.org/patient/ASCO+Resources/Patient+Guides/ASCO+Patient+Guide:+Tumor+Markers+for+Gastrointestinal+Cancers) and here (http://www.cancer.gov/cancertopics/factsheet/Detection/tumor-markers)

More discussions about biomarker
References in periodicals archive ?
Over the years, the cancer biomarkers market has evolved significantly owing to the rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R and D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies.
A comprehensive discussion of the significance of each biomarker like pharmacodynamics and toxic dynamics of protein biomarkers, analytical biomarkers, and epigenetic biomarkers is going to be held in this biomarkers congress.
Presentations span across multiple disciplines and cover topics such as discovery and validation strategies, the challenges of clinical translation, novel technologies including next-generation sequencing, companion diagnostics, the health economics value of biomarkers, reimbursement environment, and perspective on cell free biomarkers for disease diagnostics.
Cancer biomarkers can be DNA, mRNA, proteins, metabolites, or processes such as apoptosis, angiogenesis or proliferation.
Biomarkers will facilitate the combination of therapeutics with diagnostics and will thus play an important role in the development of personalized medicine.
We are very pleased to reach this agreement with Pacific Biomarkers, which broadens WuXi's biomarker capabilities in support of our clients' clinical development," said Dr.
Otherwise, biomarkers such as cardiac troponin might be considered erroneously as biomarkers of plaque instability, given that troponin increases are associated with an increased risk of a new AMI (i.
Chapter 4 focuses on drug discovery and specific-organ toxicity-related biomarkers.
infrequent, clinicians must be aware of all the possible confounders that may affect the results of biomarkers.
Professor Brown - working together with clinical trial groups, ethics committees and with support from Cancer Research UK - has carefully assembled tumor banks that will enable scientists in his lab, in collaboration with Orion, to find biomarkers for novel therapy selection and screening diagnostics and will expand Orion's exciting pipeline of diagnostic products.
The workshop focused on four topics: a) the challenge of applying new biotechnologies to the study of occupational cancer, b) markers of early biologic effect, c) inherited modifiers of risk, and d) applying genetic biomarkers to human studies.
This report describes different types of biomarkers and their discovery using various -omics technologies such as proteomics and metabolomics.